Related Experiment Video
Updated: Jul 1, 2026
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a
D Thaçi1, S Reitamo, M A Gonzalez Ensenat
1Department of Dermatology and Venerology, J.W. Goethe University, Theodor-Stern-Kai 7, Frankfurt, D-60596 Germany. thaci@em.uni-frankfurt.de
Insights
Twice-weekly proactive application of 0.03% tacrolimus ointment effectively reduced atopic dermatitis (AD) exacerbations in children. This treatment strategy helped maintain remission and decrease the need for intervention over 12 months.
Area of Science:
- Dermatology
- Pediatric Medicine
- Immunology
Background:
- Atopic dermatitis (AD) management often involves long-term use of topical anti-inflammatory agents to control disease activity.
- Intermittent, low-dose therapies are explored for managing chronic conditions like AD.
- Preventing disease exacerbations is crucial for improving patient outcomes and quality of life.
Purpose of the Study:
- To evaluate the efficacy of proactive, twice-weekly application of 0.03% tacrolimus ointment in maintaining remission of AD in children.
- To assess the impact of this regimen on reducing the incidence and severity of AD disease exacerbations (DEs).
- To compare the outcomes of proactive tacrolimus treatment versus vehicle control over a 12-month period.
Main Methods:
- A 12-month, European, multicentre, randomized study involving 267 children with AD.
- Initial open-label treatment with 0.03% tacrolimus ointment twice daily until disease control (Investigator Global Assessment [IGA] score ≤2).
- Randomization to twice-weekly proactive application of 0.03% tacrolimus ointment or vehicle, with exacerbations treated until IGA ≤2, followed by a return to randomized treatment.
Main Results:
- Proactive 0.03% tacrolimus ointment significantly reduced the number of DEs requiring substantial intervention (median difference: 1.0; P<0.001).
- The percentage of DE treatment days was significantly lower in the tacrolimus group (median difference: 6.2; P<0.001).
- Time to first DE requiring intervention was significantly increased with proactive tacrolimus (median 173 days vs. 38 days; P<0.001).
Conclusions:
- Twice-weekly proactive application of 0.03% tacrolimus ointment is effective in preventing, delaying, and reducing AD exacerbations in most pediatric patients.
- The treatment regimen demonstrated significant benefits in controlling disease flares over a 12-month period.
- Adverse event profiles were comparable between proactive tacrolimus and vehicle groups, suggesting a favorable safety profile.
Background:
Long-term treatment for atopic dermatitis (AD) using low-dose, intermittent, topical anti-inflammatory agents may control acute disease and prevent exacerbations.
Objectives:
This 12-month, European, multicentre, randomized study investigated if proactive, twice-weekly application of 0.03% tacrolimus ointment can keep AD in remission and reduce the incidence of disease exacerbation (DE) in children.
Patients And Methods:
During the initial open-label period, 267 children with AD applied 0.03% tacrolimus ointment twice daily for up to 6 weeks to all affected areas. When an Investigator Global Assessment (IGA) score of
Results:
The outcome measure was the number of DEs during the DCP that required substantial therapeutic intervention. Proactive application of 0.03% tacrolimus ointment significantly reduced the number of DEs during the DCP that required substantial therapeutic intervention (median difference: 1.0; P<0.001; Wilcoxon rank-sum test), the percentage of DE treatment days (median difference: 6.2; P<0.001; Wilcoxon rank-sum test), and increased the time to first DE requiring intervention (median: 173 vs. 38 days; P<0.001; stratified log-rank test). Differences in quality of life scores were not significant between groups. The adverse event profile was similar for both treatment approaches.
Conclusions:
Twice-weekly proactive application of 0.03% tacrolimus ointment over 12 months was effective for most paediatric study patients in preventing, delaying and reducing the occurrence of AD exacerbations.
